In today’s recent session, 0.69 million shares of the Lyell Immunopharma Inc (NASDAQ:LYEL) have been traded, and its beta is -0.42. Most recently the company’s share price was $0.97, and it changed around -$0.14 or -12.91% from the last close, which brings the market valuation of the company to $269.92M. LYEL at last check was trading at a discount to its 52-week high of $3.26, offering almost -236.08% off that amount. The share price’s 52-week low was $0.85, which indicates that the recent value has risen by an impressive 12.37% since then. We note from Lyell Immunopharma Inc’s average daily trading volume that its 10-day average is 1.16 million shares, with the 3-month average coming to 1.11 million.
Lyell Immunopharma Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.33. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended LYEL as a Hold, whereas 0 deemed it a Buy, and 1 rated it as Underweight. Lyell Immunopharma Inc is expected to report earnings per share of -0.18 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Instantly LYEL has been showing red trend so far today with a performance of -12.91% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.1600 on recent trading dayincreased the stock’s daily price by 16.38%. The company’s shares are currently down -50.17% year-to-date, but still down -12.12% over the last five days. On the other hand, Lyell Immunopharma Inc (NASDAQ:LYEL) is -15.94% down in the 30-day period. We can see from the shorts that 11.14 million shares have been sold at a short interest cover period of 7.69 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 86.14% from its current value. Analyst projections state that LYEL is forecast to be at a low of $1 and a high of $12.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Lyell Immunopharma Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -64.97 percent over the past six months and at a 13.98% annual growth rate that is well below the industry average of 16.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 8.34% in revenue this quarter, and will report an increase of 20.83% in the next quarter. The year-over-year growth rate is expected to be -74.62%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at �.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.28%. Lyell Immunopharma Inc earnings are expected to increase by 14.52% in 2024, but the outlook is negative -7.90% per year for the next five years.
LYEL Dividends
Lyell Immunopharma Inc’s next quarterly earnings report is expected to be released in December.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.06% of Lyell Immunopharma Inc shares, and 61.65% of them are in the hands of institutional investors. The stock currently has a share float of 71.73%. Lyell Immunopharma Inc stock is held by 167.0 institutions, with MWG MANAGEMENT LTD. being the largest institutional investor. By 2024-06-30, it held 7.9301% of the shares, which is about 20.16 million shares worth $29.24 million.
ORLAND PROPERTIES LTD, with 5.9366% or 15.09 million shares worth $21.89 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Price (T.Rowe) Health Sciences Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jun 30, 2024. The former held 5.92 shares worth $5.95 million, making up 2.12% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 5.82 shares worth around $5.85 million, which represents about 2.08% of the total shares outstanding.
